Search
C4 Therapeutics Inc
CCCCAdd to Watchlist
3.560USD
-0.070-1.93%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
393.62MMarket Cap
LossP/E TTM
More Details of C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
C4 Therapeutics Inc Info
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Company Executives of C4 Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
45.17K
-843.15%
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
--
-100.00%
Ms. Kelly A. Schick
Ms. Kelly A. Schick
Chief People Officer
Chief People Officer
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
45.17K
-843.15%
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.54%
Morgan Stanley & Co. LLC
8.10%
RA Capital Management, LP
7.24%
Lynx1 Capital Advisors LLC
6.33%
Vanguard Capital Management, LLC
3.49%
Other
66.30%
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.54%
Morgan Stanley & Co. LLC
8.10%
RA Capital Management, LP
7.24%
Lynx1 Capital Advisors LLC
6.33%
Vanguard Capital Management, LLC
3.49%
Other
66.30%
Shareholder Types
Shareholders
Proportion
Investment Advisor
24.05%
Hedge Fund
20.77%
Research Firm
12.49%
Venture Capital
7.36%
Investment Advisor/Hedge Fund
6.20%
Individual Investor
1.88%
Private Equity
1.28%
Bank and Trust
0.59%
Pension Fund
0.21%
Other
25.17%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
296
76.03M
69.01%
-8.78M
2025Q4
294
70.34M
70.90%
+17.39M
2025Q3
308
52.96M
108.83%
-2.15M
2025Q2
306
55.08M
118.23%
-10.19M
2025Q1
320
64.50M
110.39%
-13.86M
2024Q4
320
64.84M
109.43%
+173.51K
2024Q3
315
64.67M
104.71%
+3.40M
2024Q2
309
61.26M
103.56%
+2.76M
2024Q1
313
58.50M
89.36%
-2.80M
2023Q4
309
47.27M
101.07%
+10.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 Asset Management, L.P.
9.44M
9.67%
+961.68K
+11.34%
Dec 31, 2025
Morgan Stanley & Co. LLC
8.96M
9.18%
+4.09M
+84.18%
Dec 31, 2025
RA Capital Management, LP
8.00M
8.2%
--
--
Dec 31, 2025
Lynx1 Capital Advisors LLC
7.10M
7.27%
--
--
Dec 31, 2025
Soleus Capital Management, L.P.
3.80M
3.9%
-3.25M
-46.07%
Dec 31, 2025
Bain Capital Life Sciences Investors, LLC
3.13M
3.21%
+1.11M
+55.05%
Dec 31, 2025
Wasatch Global Investors Inc
4.34M
4.45%
-507.82K
-10.46%
Dec 31, 2025
Two Sigma Investments, LP
2.58M
2.64%
+979.98K
+61.33%
Dec 31, 2025
BofA Global Research (US)
2.39M
2.45%
+334.42K
+16.29%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Fidelity Enhanced Small Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
